Ketamine for Veterans With Parkinson's Disease
Phase 2
80
about 4.2 years
40–80
1 site in CA
What this study is about
Researchers are testing if ketamine, given as an intravenous (IV) injection, can improve depression in Veterans with Parkinson's disease. The trial will also examine how ketamine affects neuroplasticity and inflammation in these individuals. It aims to determine if ketamine could be a useful treatment for Veterans with Parkinson's disease.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ketamine
- 2.Take Remimazolam
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), remimazolam
injection, intravenous
Primary: Montgomery-Asberg Depression Rating Scale (MADRS)
Secondary: Enhanced Scale for the Assessment of Positive Symptoms for Parkinson's Disease (eSAPS- PD), Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale-7 (HAMD-7), Incidence, severity, and frequency of Adverse Events (AEs) including Treatment- Emergent AEs (TEAEs) and Serious AEs (SAEs), Montgomery-Asberg Depression Rating Scale (MADRS), Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Patient- Reported Outcomes Measurement Information System (PROMIS®), Quality of Life in Neurological Disorders (Neuro-QoLTM)
Neurology